Please login or register to print this page.

VIEW TAGS

Articles tagged ‘atrial flutter’

May 28, 2015

“Isolated” AF is not benign

Long-term atrial fibrillation (AF)-related stroke and mortality risks are similar between individuals with and without secondary AF precipitants, according to a study published recently in Circulation.1

read more

December 19, 2014

AF-related strokes on increase, despite more anticoagulation

Numbers of atrial fibrillation (AF)-related incident ischaemic strokes at age ≥80 years have trebled over the last 25 years, despite the introduction of anticoagulants, and are projected to treble again by 2050, along with the numbers of systemic emboli, according to a study published recently in Circulation.1

read more

December 20, 2013

Still “chipping away” at ethnic differences in AF

White people have an increased risk of atrial fibrillation (AF) whether compared with black, Asian, or Hispanic people, with the heightened risk being most pronounced in the absence of cardiovascular comorbidities, according to a study1 published recently in Circulation.

read more

October 30, 2013

First non-thermal ablation using photodynamic therapy

Non-thermal photodynamic therapy (PDT)-mediated catheter ablation is a potentially novel treatment for cardiac arrhythmias, according to a report1 on the first non-thermal ablation using a custom-made deflectable laser catheter (Arai-Medphoton), published recently in Circulation: Arrhythmia and Electrophysiology.

read more

July 7, 2009

FDA Approves dronaderone for patients with Atrial Fibrillation or Atrial Flutter

It has recently been announced that the U.S. Food and Drug Administration (FDA) has approved the use of dronaderone (Multaq®) for patients with atrial fibrillation (AF) or atrial flutter (AFL). Multaq® is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.

read more

June 8, 2009

New heart failure data from ATHENA

Use of the antiarrhythmic drug dronedarone significantly reduced the risk of hospitalisation due to cardiovascular events or death in patients with paroxysmal or persistent atrial fibrillation or flutter in the ATHENA trial. New data are now available on trial patients with heart failure.

read more

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.